Antibody & AOC Commercial Manufacturing
Successful commercialization of antibody therapeutics and antibody-oligonucleotide conjugates (AOCs) requires robust manufacturing processes, scalable production capabilities, and comprehensive quality systems. Protheragen provides integrated commercial manufacturing services for antibody drugs and AOC therapeutics, supporting clients from late-stage clinical development through regulatory approval and commercial supply. Leveraging advanced biologics manufacturing platforms, GMP-compliant facilities, and experienced technical teams, we provide reliable Drug Substance (DS) and Drug Product (DP) manufacturing solutions to ensure consistent product quality, regulatory compliance, and long-term supply stability.
Overview of Antibody & Commercial Manufacturing
Commercial Manufacturing refers to the large-scale production of therapeutic products under Good Manufacturing Practice (GMP) conditions after completion of process development and clinical manufacturing stages. It is a critical phase in the pharmaceutical development lifecycle, ensuring that approved or late-stage clinical products can be manufactured consistently, safely, and efficiently to meet commercial supply requirements.
For complex biologics, including monoclonal antibodies and antibody-oligonucleotide conjugates (AOCs), commercial manufacturing requires robust production processes, validated manufacturing procedures, comprehensive quality control systems, and strict regulatory compliance. It involves the transition from development-scale processes to routine GMP production, including large-scale drug substance manufacturing, drug product formulation, aseptic filling, packaging, and ongoing process monitoring.
A successful commercial manufacturing strategy ensures product consistency, scalability, supply reliability, and compliance with global regulatory standards, supporting the long-term availability of innovative therapies for patients worldwide.
Our Services
Building on robust process development, analytical capabilities, and GMP manufacturing expertise, Protheragen provides comprehensive commercial manufacturing solutions for antibody and antibody-oligonucleotide conjugate (AOC) therapeutics. Our services are designed to support the transition from late-stage clinical development to commercial production, ensuring scalable manufacturing processes, consistent product quality, and reliable supply throughout the product lifecycle.
Antibody Drug Substance Manufacturing
Protheragen provides GMP manufacturing services for monoclonal antibodies and recombinant antibody therapeutics, covering the complete upstream and downstream manufacturing workflow.
Our capabilities include:
Upstream Manufacturing
- Mammalian cell culture using CHO and other expression platforms
- Seed train development and scale-up
- Fed-batch and perfusion production processes
- Large-scale bioreactor manufacturing
Downstream Manufacturing
- Protein A affinity purification
- Chromatography process optimization
- Viral clearance and filtration processes
- Ultrafiltration and diafiltration (UF/DF)
- Bulk drug substance preparation and storage
Our flexible manufacturing platforms support different development stages, from clinical supply production to commercial-scale manufacturing.
AOC Drug Substance Manufacturing
Antibody-oligonucleotide conjugates combine antibody targeting capability with oligonucleotide therapeutic activity, creating unique manufacturing challenges due to their complex molecular structures.
Protheragen provides specialized AOC manufacturing solutions including:
Antibody Preparation
- Recombinant antibody production
- Antibody purification and characterization
- Quality assessment before conjugation
Conjugation Manufacturing
- Site-specific and chemical conjugation processes
- Optimization of conjugation conditions
- Control of drug-to-antibody ratio (DAR) and conjugation efficiency
- Reduction of process-related impurities
AOC Purification and Characterization
- Conjugate purification
- Aggregation analysis
- Free oligonucleotide and antibody monitoring
- Structural and functional characterization
Our integrated antibody and oligonucleotide expertise enables efficient scale-up of AOC production from development batches to GMP manufacturing.
Drug Product Manufacturing & Fill-Finish
Protheragen provides GMP-compliant formulation and fill-finish services for antibody and AOC therapeutics, supporting injectable drug product manufacturing.
Capabilities include:
Formulation Development
- Buffer and excipient optimization
- Stability improvement
- High-concentration formulation development
- Lyophilized formulation development
Aseptic Manufacturing
- Sterile filtration
- Aseptic filling
- Vial filling and packaging
- Visual inspection and labeling
Our manufacturing solutions support multiple injectable dosage forms, helping clients achieve reliable clinical and commercial product supply.
Process Scale-Up and Technology Transfer
Successful commercialization requires seamless transition from laboratory development to GMP manufacturing.
Our technology transfer services include:
- Process transfer from internal R&D or external partners
- Manufacturing process assessment
- Scale-up strategy development
- Equipment and process compatibility evaluation
- Engineering and GMP batch production
Experienced manufacturing teams ensure efficient transfer while maintaining product quality attributes and process consistency.
Process Validation & Commercial Supply
To support regulatory approval and long-term market supply, Protheragen provides comprehensive validation and lifecycle management services.
Services include:
Process Validation
- Engineering batch production
- Process performance qualification (PPQ)
- Critical process parameter evaluation
- Continued process verification (CPV)
Commercial Supply Support
- Routine GMP batch manufacturing
- Batch release testing
- Stability sample production
- Post-approval manufacturing support
Our quality-driven manufacturing system helps ensure reliable supply throughout the product lifecycle.
Manufacturing Capabilities
Protheragen offers scalable manufacturing solutions designed for antibody and AOC products. Key capabilities include:
| Capability |
Description |
| Cell Culture Platform |
CHO-based mammalian expression systems |
| Production Scale |
Flexible small-to-large scale manufacturing |
| Drug Substance |
Antibody and AOC GMP manufacturing |
| Drug Product |
Formulation, sterile filling and packaging |
| Quality System |
GMP-compliant quality management |
| Regulatory Support |
IND/BLA and global regulatory assistance |
The manufacturing platform includes dedicated production areas, QC laboratories, analytical development facilities, and pilot-scale manufacturing capabilities to support the entire product lifecycle.
Quality & Regulatory Compliance
Commercial manufacturing requires strict control of product quality and regulatory compliance. Protheragen has established a comprehensive quality management system aligned with global regulatory requirements, including:
- GMP compliance
- Quality risk management
- Deviation and CAPA management
- Change control systems
- Documentation management
- Regulatory inspection preparation
Our quality system supports regulatory expectations from agencies such as FDA, EMA, NMPA, and other international regulatory authorities.
Why Choose Protheragen
Integrated Development-to-Manufacturing Platform
- Complete CMC development support
- Antibody and AOC integrated manufacturing capabilities
- Seamless transition from clinical to commercial production
Flexible Production Capacity
- Scalable manufacturing solutions
- Support for different batch sizes and market demands
- Rapid response to project requirements
Experienced Technical Team
- Expertise in biologics manufacturing
- Experience with complex antibody formats
- Strong process development and GMP production capabilities
Regulatory-Focused Manufacturing
- Comprehensive documentation support
- Global regulatory compliance
- Lifecycle management throughout commercialization
As antibody and antibody-oligonucleotide conjugate (AOC) therapies continue to advance toward commercialization, reliable manufacturing capabilities are essential for ensuring product quality, regulatory compliance, and long-term supply stability. Protheragen combines integrated CMC expertise, GMP manufacturing platforms, and flexible production solutions to support the complete transition from clinical development to commercial manufacturing. With our comprehensive capabilities in drug substance production, drug product manufacturing, process validation, and quality management, we help partners efficiently bring innovative antibody-based therapeutics to the global market. Contact us today to discuss your antibody and AOC manufacturing requirements and explore a tailored solution for your development program.
Reference
- Gronemeyer P, et al. "Trends in Upstream and Downstream Process Development for Antibody Manufacturing" Bioengineering. 2014; 1(4):188-212.
